4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma.

Saved in:
Bibliographic Details
Title: 4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma.
Authors: Vasudev NS; Department of Medical Oncology, St James's University Hospital, Leeds, UK. n.vasudev@leeds.ac.uk., Aleem U; Department of Medical Oncology, Christie Hospital, Manchester, UK., Humphries K; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Pillai M; Department of Medical Oncology, Christie Hospital, Manchester, UK., Pickwell-Smith B; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Ralph C; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Jagdev S; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Simpson J; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Dearden H; Department of Medical Oncology, St James's University Hospital, Leeds, UK., Waddell T; Department of Medical Oncology, Christie Hospital, Manchester, UK.
Source: BJC reports [BJC Rep] 2026 May 08; Vol. 4 (1). Date of Electronic Publication: 2026 May 08.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918752188106676 Publication Model: Electronic Cited Medium: Internet ISSN: 2731-9377 (Electronic) Linking ISSN: 27319377 NLM ISO Abbreviation: BJC Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2731-9377
DOI:10.1038/s44276-026-00224-y